MannKind Corporation MNKD
Set alert
At close · Oct 30
After hours · Oct 30, 4:17 PM ET
- YTD
- -38.27%
- 1 year
- -36.94%
- Open
- 3.50
- Prev close
- 3.50
- Mkt cap
- 1.13B
- Vol
- 2.01M
- Avg vol
- 4.24M
- EPS
- -0.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.45
- High
- 3.57
- Forward P/E
- 25.93
- Beta
- 1.08
- Short ratio
- 4.69
- Inst. own
- 57.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 3.60
- 200-d avg
- 3.74
- 1y target
- 8.08
5D chart
Signals (60)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| RSI: Overbought | Oct 28, 12:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:10 PM | 6 days ago |
| RSI: Oversold | Oct 26, 1:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 6 days ago |
News
3 days ago globenewswire.com
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after…
1 week ago marketbeat.com
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF,…
-
1 week ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
1 week ago benzinga.com
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
1 week ago benzinga.com
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.
-
1 week ago benzinga.com
Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10
Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.
2 weeks ago globenewswire.com
MannKind to Participate in the Chardan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a…
-
2 weeks ago benzinga.com
Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across…
3 weeks ago globenewswire.com
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across…
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on MannKind, Lowers Price Target to $5
Truist Securities analyst Gregory Renza maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $6 to $5.
1 month ago marketbeat.com
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major…
-
1 month ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
1 month ago benzinga.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.
1 month ago benzinga.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.
-
1 month ago benzinga.com
MannKind And Rose Pharma Enter Into Worldwide Licensing And Collaboration Agreement To Develop ROSE-010 Technosphere For Weight Management
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential…
1 month ago globenewswire.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential…
2 months ago globenewswire.com
MannKind to Present at Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
2 months ago zacks.com
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
-
2 months ago benzinga.com
MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants
Up to 12,853,470 SharesCommon StockThis prospectus supplement relates to the offer and resale by the selling stockholders (the "selling stockholders") identified in this prospectus supplement of up…
2 months ago seekingalpha.com
MannKind: New Approvals Majorly Increase MannKind's Prospects
Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity…
-
2 months ago benzinga.com
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13
Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $14 to $13.
2 months ago seekingalpha.com
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
MannKind Q2 Earnings Call Highlights
MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased…
2 months ago zacks.com
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
2 months ago zacks.com
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.
-
2 months ago benzinga.com
MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate
MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $(0.00) by Infinity percent. This is a 120 percent decrease over earnings of $0.05…
2 months ago globenewswire.com
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and…
3 months ago seekingalpha.com
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14
Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $11 to $14.
3 months ago marketbeat.com
MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
MannKind NASDAQ: MNKD reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study…
3 months ago reuters.com
MannKind injection helps heart failure patients avoid ER infusions
We also report on an experimental diagnostic approach that can detect tuberculosis exposure and infection at an earlier stage than current methods.
-
3 months ago benzinga.com
MannKind Reports Topline Results From INFLO-1, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Dry Powder Inhalation In Patients With Idiopathic Pulmonary Fibrosis
Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in…
3 months ago globenewswire.com
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
3 months ago benzinga.com
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.
-
3 months ago benzinga.com
MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung…
-
3 months ago benzinga.com
MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney Disease
Furoscix ReadyFlow is an at-home treatment option designed to help adults with heart failure or chronic kidney disease address fluid overload earlier, before worsening symptoms may lead to emergency…
-
4 months ago benzinga.com
MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE…
-
4 months ago benzinga.com
Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize…
4 months ago benzinga.com
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends
Cramer put Photronics in the penalty box due to poor results. He praised Woodward and warned against Occidental Petroleum.
-
5 months ago benzinga.com
MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopathic Pulmonary Fibrosis
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in…
-
5 months ago benzinga.com
MannKind To Host Conference Call At 4:30 p.m. ET On May 29 To Discuss FDA Approval Of Pediatric Use Of Afrezza
MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older…
-
5 months ago benzinga.com
MannKind Wins FDA Approval For Pediatric Use Of Inhaled Insulin Afrezza In Children Ages 6 And Older With Diabetes
Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care…
-
5 months ago benzinga.com
MannKind To Present New Clinical And Real‑World Data On Afrezza Inhalation Powder And Analyses Of Furoscix In Patients With Co-Morbidities At The American Diabetes Association's 2026 Scientific Sessions, June 5-8
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung…
-
5 months ago benzinga.com
RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $4.75
RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and raises the price target from $3.5 to $4.75.
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $10
Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.
-
5 months ago benzinga.com
Mizuho Maintains Outperform on MannKind, Lowers Price Target to $7
Mizuho analyst Anthony Petrone maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price target from $8 to $7.
5 months ago benzinga.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on MannKind, Raises Price Target to $10
HC Wainwright & Co. analyst Brandon Folkes maintains MannKind (NASDAQ:MNKD) with a Buy and raises the price target from $8 to $10.
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
